IN THE CLAIMS

The status of each claim in the present application is listed below.

Claims 1-37: (Canceled).

38. (Previously Presented) An amphipathic glycopeptide, the amino acid sequence of which comprises an N- terminal opioid message sequence, a C-terminal helical address sequence, and a linker sequence between the message sequence and the helical address sequence, wherein

the C-terminal helical address sequence has a length of nine amino amino acids, and

at least one of the amino acid residues of the peptide is glycosylated.

39. (Previously Presented) The glycopeptide of Claim 38, wherein the N-terminal opioid message sequence is Y-t-G-F- or Y-a-G-F-.

40. (Previously Presented) The glycopeptide of Claim 38, wherein the N-terminal opioid message sequence is Y-t-G-F-L-P-.

41. (Currently Amended) The glycopeptide of Claim 38, wherein the N-terminal opioid message sequence is Y-t-G-F-L-βA- ~~Y-t-G-F-L-pA-~~.

42. (Previously Presented) The glycopeptide of Claim 38, wherein the N-terminal opioid message sequence is Y-t-G-F-L-G-G-.

43. (Previously Presented) The glycopeptide of Claim 38, which is a glycosylated enkephalin.

44. (Previously Presented) The glycopeptide of Claim 38, which is a glycosylated endorphin.

45. (Previously Presented) The glycopeptide of Claim 38, which adopts a helical conformation in the presence of a lipid bilayer.

46. (Previously Presented) The glycopeptide of Claim 38, which is substantially non-helical in water in the absence of a lipid bilayer.

47. (Previously Presented) The glycopeptide of Claim 38, which is substantially non-helical in water in the absence of a lipid bilayer and adopts a helical conformation in the presence of a lipid bilayer.

48. (Previously Presented) The glycopeptide of Claim 38, wherein one amino acid residue is glycosylated.

49. (Previously Presented) The glycopeptide of Claim 38, wherein two amino acid residues are glycosylated.

50. (Previously Presented) The glycopeptide of Claim 38, which comprises at least one serine residue that is glycosylated.

51. (Previously Presented) The glycopeptide of Claim 38, which comprises 2 serine residues that are glycosylated.

52. (Previously Presented) The glycopeptide of Claim 38, which is glycosylated with a glycosyl unit having at most 8 saccharide units.

53. (Previously Presented) The glycopeptide of Claim 38, which is glycosylated with a glycosyl unit having at most 4 saccharide units.

54. (Previously Presented) The glycopeptide of Claim 38, which is glycoslated with a glycosyl unit having at most 2 saccharide units.

55. (Previously Presented) The glycopeptide of Claim 38, which is glycoslated with a glycosyl unit having at most 1 saccharide unit.

56. (Previously Presented) The glycopeptide of Claim 38, which contains one serine glucoside residue.

57. (Previously Presented) The glycopeptide of Claim 38, which contains 2 serine glucoside residues.

58. (Previously Presented) The glycopeptide of Claim 38, which comprises at least 14 amino acid residues.

59. (Previously Presented) The glycopeptide of Claim 38, which comprises at least 15 amino acid residues.

60. (Previously Presented) The glycopeptide of Claim 38, which comprises at least 17 amino acid residues.

61. (Previously Presented) The glycopeptide of Claim 38, which comprises at least 19 amino acid residues.

62. (Previously Presented) The glycopeptide of Claim 38, which comprises at most 60 amino acid residues.

63. (Previously Presented) The glycopeptide of Claim 38, which has at most 5% helicity as measured by circular dichroism in water and at least 10% helicity in the presence of a lipid bilayer.

64. (Previously Presented) The glycopeptide of Claim 38, which crosses the blood-brain-barrier.

65. (Previously Presented) The glycopeptide of Claim 38, which is selective for at least one receptor selected from the group consisting of the delta opioid receptor, mu opioid receptor and kappa opioid receptor.

66. (Previously Presented) A pharmaceutical composition comprising the glycopeptide of Claim 38 and at least one pharmaceutically acceptable carrier and/or excipient.

67. (Currently Amended) A method of relieving pain, comprising administering an effective amount of the glycopeptide of Claim 38 to a subject in need thereof.

68. (Previously Presented) A method of providing analgesia, comprising administering an effective amount of the glycopeptide ~~glycopeptides~~ of Claim 38 to a subject in need thereof.

69. (Currently Amended) A method of treating anxiety, depression, obesity, anorexia nervosa, phobias, schizophrenia, Parkinson's disease or ~~and~~ Alzheimer's disease, comprising administering an effective amount of the glycopeptide ~~glycopeptides~~ of Claim 38 to a subject in need thereof.